Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | BDKRB1 | P46663 | 11/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6029674 | 1.00 | ALDH1A1 (1.00) | ALDH1A1POLBBDKRB1KMT2AMAPT | |
| SCHEMBL6407081 | 0.93 | ALDH1A1 (0.86) | ALDH1A1POLBBDKRB1KMT2AMAPT | |
| SCHEMBL22563749 | 0.88 | ALDH1A1 (0.77) | ALDH1A1POLBBDKRB1MAPTGAA | |
| SCHEMBL20457664 | 0.88 | ALDH1A1 (0.77) | ALDH1A1POLBBDKRB1MAPTGAA | |
| SCHEMBL15599334 | 0.87 | ALDH1A1 (0.77) | ALDH1A1POLBBDKRB1KMT2AGAA | |
| SCHEMBL4424964 | 0.86 | ALDH1A1 (0.76) | ALDH1A1POLBBDKRB1KMT2AMAPT | |
| SCHEMBL4432052 | 0.86 | ALDH1A1 (0.76) | ALDH1A1POLBBDKRB1KMT2AMAPT | |
| SCHEMBL4427205 | 0.85 | BDKRB1 (0.78) | ALDH1A1POLBBDKRB1KMT2AMAPT | |
| SCHEMBL6404693 | 0.85 | BDKRB1 (0.78) | ALDH1A1POLBBDKRB1KMT2AMAPT | |
| SCHEMBL6406344 | 0.85 | POLB (0.73) | ALDH1A1POLBBDKRB1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020591-A1 | 2-Quinoxalinone derivatives as bradykinin antagonists and novel compounds | SU DAI-SHI (US) | 2005-01-27 | — | — | US | claimed |
| US-20050020591-A1 | 2-Quinoxalinone derivatives as bradykinin antagonists and novel compounds | SU DAI-SHI (US) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020591-A1 | 2-Quinoxalinone derivatives as bradykinin antagonists and novel compounds | BDKRB1, BDKRB2, LTB4R2 | ALDH1A1 3743/4885POLB 2903/4885BDKRB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.